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Asymmetric synthesis of (S)-phenylacetylcarbinol
– closing a gap in C–C bond formation†
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Robert Westphal,a,e Constantin Vogel,f,g Ulf Menyes,h Martin Erhardt,b
Michael Müller,d Martina Pohla and Dörte Rother*a
(S)-Phenylacetylcarbinol [(S)-PAC] and its derivatives are valuable
intermediates for the synthesis of various active pharmaceutical
ingredients (APIs), but their selective synthesis is challenging. As
no highly selective enzymes or chemical catalysts were available,
we used semi-rational enzyme engineering to tailor a potent bio-
catalyst to be >97% stereoselective for the synthesis of (S)-PAC. By
optimizing the reaction and process used, industrially relevant
product concentrations of >48 g L−1 (up to 320 mM) were
achieved. In addition, the best enzyme variant gave access to a
broad range of ring-substituted (S)-PAC derivatives with high
stereoselectivity, especially for meta-substituted products.
The last few decades have seen site-directed engineering of
enzymes accelerating the use of biocatalysis for the production
of pharmaceuticals and fine chemicals. The high stereo-
selectivity and regioselectivity of many biocatalysts allow
complex drugs to be produced and meet the special require-
ments of the pharmaceutical industry.1 α-Hydroxy ketones are
versatile building blocks for the pharmaceutical and chemical
industry.2 Their bifunctional nature and the presence of one
prochiral carbonyl group next to the stereocentre make them
amenable to further transformations3 such as reductive amin-
ation. A well-known example, which was patented in 1932, is
the fermentative production of (R)-PAC, which can be sub-
sequently reductively aminated to (1R,2S)-ephedrine.4 Also, the
(S)-configured counterpart (S)-PAC is a valuable intermediate
for the synthesis of phenylpropanolamine pharmaceuticals
such as the appetite suppressant cathine [(1S,2S)-2-amino-1-
phenylpropan-1-ol, (+)-norpseudoephedrine] or other active
pharmaceutical ingredients (APIs, Fig. 1).5
The chemical synthesis of the C–C bond in a highly chemo-
and stereoselective manner is very challenging.6 This challenge
has been almost completely met by biocatalytic approaches
using thiamine diphosphate (ThDP)-dependent enzymes (see
Fig. 1).7
Although some engineered variants of the pyruvate de-
carboxylases from Zymomonas mobilis (ZmPDC-E473G)8a and
Acetobacter pasteurianus (ApPDC-E469G)8b are available that
catalyse the cross-benzoin reaction using either acetaldehyde
or pyruvate as donors and benzaldehyde as the acceptor, the
enantiomeric excess (ee) for (S)-PAC has not been reported to
exceed 60–87% and depends on the reaction conditions.8,9
This level of stereoselectivity is not suﬃcient for industrial
needs, which also holds for chemical asymmetric syntheses
which do not deliver convenient enantiomeric product purity
either. Better results were recently obtained with a new ThDP-
dependent acetoin:dichlorophenolindo-phenol oxidoreductase
(Ao:DCPIP OR), which catalyses the formation of (S)-PAC with
94% ee using the more complex methylacetoin as a donor.2c,10
The simplest strategy producing (S)-PAC involves the regio-
and enantioselective formation of an acetaldehyde–benz-
aldehyde cross-benzoin product with an enolisable aliphatic
aldehyde and a plain aromatic aldehyde. Nevertheless, the use
of acetaldehyde, although a valuable building block for aldol
additions, is exceptionally challenging due to its high reactiv-
ity, its tendency to participate in undesired side reactions, and
its diﬃcult handling.11 Therefore, the biocatalytic access to (S)-
PAC from acetaldehyde and benzaldehyde requires a synergis-
tic enzyme and reaction engineering in order to ensure
enzyme stability and to achieve high product concentrations
with ee values of more than 95%. One option is to use pyru-
vate, which is decarboxylated to acetaldehyde prior to
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carboligation in the same active site of several ThDP-depen-
dent enzymes.12
To set up a scalable process for the chemo- and stereo-
selective synthesis of (S)-PAC, we started with the above-
mentioned variant ApPDC-E469G. This variant proved to be an
excellent catalyst for the synthesis of several (S)-PAC-derivati-
ves.8b,13 Due to optimal stabilisation of both substrates in the
active site of this variant, various (S)-PAC derivatives could be
rationally designed with high chemo- and stereoselectivity and
good percent conversions. Still, the synthesis of (S)-PAC itself
remained challenging. When used as a purified enzyme, the
ApPDC-E469G variant was shown to catalyse the formation of
(S)-PAC with an ee of ∼60% in the presence of DMSO as a
cosolvent,8b,c whereas an 87% ee was achieved when the reac-
tion was performed solely in buﬀer (see Fig. 2B).9 Since chro-
matographically purified enzymes are expensive for industrial
applications, enzyme variants were also studied as whole cell
biocatalysts using recombinant Escherichia coli cells. While the
(S)-PAC concentration could be significantly increased (up to
156 mM), the stereoselectivity dropped to 43% ee.13b
In order to meet the industrial demands of high stereo-
selectivity, the use of inexpensive whole cells or crude cell
extracts, and high product concentration for the synthesis of
(S)-PAC, the first optimisation strategy concerned the improve-
ment of the stereoselectivity of the enzyme. The goal was to
obtain a more stereoselective biocatalyst that maintained its
selectivity also when used as a whole cell biocatalyst.
Due to comprehensive structure–function studies of ThDP-
dependent enzymes, factors controlling the stereoselectivity of
these enzymes are well understood.7 The stereoselectivity of
the formation of PAC by these enzymes is induced by the rela-
tive orientation of the substrates prior to the formation of the
C–C bond (carboligation; for mechanism see ESI, chapter S1†).
(R)-PAC is produced when the side chains of the ThDP-bound
donor (hydroxyethyl-ThDP, derived by addition of acetaldehyde
or decarboxylated pyruvate) and benzaldehyde are orientated
in a parallel manner (Fig. 2A). Replacement of the glutamate
residue at position 469 with glycine has been shown to open a
so-called (S)-pocket (Fig. 2B) and enables an antiparallel orien-
tation of the substrates, yielding (S)-PAC with a moderate ee of
about 60 %, depending on the enzyme formulation and the
reaction conditions.8b,c,9,13b
To improve the situation, an enzyme engineering approach
similar to the one reported by Westphal et al.14 involving site-
saturation mutagenesis of two additional residues was applied
to reduce the formation of the R enantiomer (see Fig. 2C and
D). Isoleucine 468 was expected to be responsible for two
eﬀects: impairment of an optimal antiparallel substrate orien-
tation for (S)-PAC formation due to its location at the entrance
of the (S)-pocket, and stabilisation of the benzaldehyde in a
Fig. 1 New (S)-selective variants of pyruvate decarboxylase from Acetobacter pasteurianus (ApPDC) complement the carboligation toolbox for produ-
cing mixed aromatic-aliphatic α-hydroxy ketones. The availability of these variants now close a gap in the asymmetric synthesis of the envisaged APIs.
Fig. 2 Schematic representation of the active site of ApPDC. The legends explain the eﬀect of diﬀerent amino acid residues on the preferred orien-
tation of the ThDP-bound donor substrate acetaldehyde, derived from pyruvate after decarboxylation (green rectangle) and the aromatic acceptor
aldehyde (blue hexagon). The relative orientation of both substrates to each other deﬁnes the stereoselectivity of the product. (The ﬁgures refer to
the stereoselectivities achieved with puriﬁed enzyme.)
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parallel orientation by forming a hydrophobic interaction with
the phenyl ring. In addition, tryptophan at position 543
(which is part of the C-terminal α-helix covering the entrance
to the active site) is located 2–3 Å from the benzaldehyde when
arranged in a parallel orientation (Fig. 2C; for PyMOL model-
ling see ESI, chapter S1†). At this distance, aromatic π-stacking
interactions are highly likely,15 and such interactions might
stabilize the benzaldehyde in the undesired (“pro-R”) orien-
tation. Smaller aromatic residues such as phenylalanine in
this position (Fig. 2D) should increase the distance between
the aromatic residues to 5–6 Å, making π-stacking interactions
unlikely, as has already been shown for similar ThDP-depen-
dent enzymes.14b Thus, positions I468 and W543 were selected
as targets for further site-saturation mutagenesis studies based
on the ApPDC-E469G variant. Screening assay conditions (syn-
thesis of (S)-PAC from 20 mM benzaldehyde and 200 mM pyru-
vate with crude cell extracts) were performed as described in
the ESI (chapter S4†). In the chiral-phase HPLC-based screen-
ing assay, we focused on the identification of enzyme variants
with an improved ee value for (S)-PAC compared to
ApPDC-E469G. Respective genes of positive screening hits
(Fig. 3) were isolated and sequenced. Replacement of isoleu-
cine at position 468 with glycine, which is the smallest amino
acid residue (Fig. 3, ApPDC-E469G/I468G) or with leucine
(ApPDC-E469G/I468L) increased the stereoselectivity of the (S)-
PAC formation. Since larger residues at position 468 did not
result in enhanced stereoselectivity, the hypothesis of a
blocked entrance to the (S)-pocket by large amino acid resi-
dues at position 468 was supported. The putative π-stacking
interaction, seen between tryptophan at position 543 with
benzaldehyde in the undesired parallel configuration (see
Fig. 2C), seemed to be reduced by introducing instead phenyl-
alanine (ApPDC-E469G/W543F) or histidine
(ApPDC-E469G/W543H) in this position, leading to increased
stereoselectivity. In addition to electronic eﬀects, steric eﬀects
also seemed to influence the stereo preference. In fact, the
small and non-aromatic leucine (ApPDC-E469G/W543L)
resulted in a decreased ee for (S)-PAC compared to the other
variants (Fig. 3). As alanine was not encoded in the initial
library, we performed an additional QuikChange™ PCR (ESI,
chapter S2†) to replace I468 with alanine. Whereas no activity
was found for the triple variant ApPDC-E469G/I468A/W543H,
variant ApPDC-E469G/I468A/W543F was active and showed the
highest stereoselectivity of the variants in all tested prep-
arations. Conclusively, in this triple variant the (S)-pocket size
and destabilisation of the parallel acceptor annealing were
optimally combined, leading to formation of (S)-PAC with ee
values up to 97% and percent conversions up to 99% (ESI,
chapter S4†). Noticeably, for the triple variant
ApPDC-E469G/I468A/W543F, high stereoselectivities were
achieved with all three catalyst formulations (crude cell extract,
wet cells, and purified enzyme) (Fig. 3) under the applied con-
ditions. In contrast, for ApPDC-E469G, the diﬀerences in ee
values of (S)-PAC observed with diﬀerent catalyst preparations
matched well with the previous results noted above.8b,c,9
Exemplarily, (S)-PAC synthesis was performed in preparative
batch scale (250 mL) with the ApPDC-E469G/I468A/W543F
variant using 40 mM benzaldehyde and 120 mM pyruvate (for
further details and results, see ESI S4.2.3.†). (S)-PAC was
obtained with a purity of 74% according to quantitative NMR,
with 2-propanol, remaining benzaldehyde, and the regio-
isomer 2-hydroxypropiophenone as the predominant impuri-
ties. As depicted in Fig. S6 (ESI†), the initially high ee (>97%)
dropped slightly to 94% during the course of the reaction,
most likely due to the instability of (S)-PAC under the applied
reaction conditions (see also ESI chapter S6.3†). As our aim
was to enzymatically convert the partially unstable (S)-PAC to
active pharmaceutical ingredients, such as norephedrine and
norpseudoephedrine according to Sehl et al.,5b we did not
pursue on optimisation of the (S)-PAC purification.
With the newly engineered triple variant at hand, the
second goal was to investigate the synthetic potential of this
new biocatalyst with respect to S-selective carboligation
of functionalised α-hydroxy ketones. Fig. 4 shows the
broad range of (S)-PAC derivatives accessible with
ApPDC-E469G/I468A/W543F and the two other indicated var-
iants. Specifically a broad range of meta-substituted derivatives
as well as several ortho-substituted products were obtained
with good to excellent stereoselectivity combined with good
Fig. 3 Stereoselectivities of the new ApPDC-variants for the synthesis
of (S)-PAC. The diﬀerent variants were tested as wet cells, crude cell
extracts, and puriﬁed enzymes. Reaction conditions: wet cells – 20 mM
benzaldehyde; 200 mM pyruvate; 50 mM KPi-buﬀer (pH 6.5), 2.5 mM
MgSO4; 0.1 mM ThDP; 20 °C; 800 rpm, 800 µL reaction volume in
1.5 mL closed glass vials, whole cell catalyst concentration of 50
mg mL−1. Crude cell extract – 20 mM benzaldehyde; 200 mM pyruvate;
50 mM KPi-buﬀer (pH 6.5), 2.5 mM MgSO4; 0.1 mM ThDP; 20 °C; 800
rpm, 500 µL reaction volume in a 96-well sheet; see ESI chapter
2.1.4–2.1.5† for the catalyst concentration. Puriﬁed enzyme – 40 mM
benzaldehyde; 200 mM pyruvate; 50 mM KPi-buﬀer with three diﬀerent
pH values, 2.5 mM MgSO4; 0.1 mM ThDP; 22 °C; 800 rpm, 800 µL reac-
tion volume in 1.5 mL closed glass vials; protein concentration of
1 mg mL−1.
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percent conversions. para-Substituted derivatives, however,
were mainly obtained with an excess of the (R)-enantiomer
(Fig. 4 and ESI, chapter S7†). The wildtype enzyme was found
to be (R)-selective for all functionalized substrates.
Our purpose was to meet the technical demands of stereo-
selectivity and high product concentrations for the production
of (S)-PAC by carrying out reaction engineering. To increase
the solubility of benzaldehyde (∼60 mM under the applied
conditions; ESI, chapter S5†), while keeping the reaction
system monophasic to avoid inactivation of the biocatalyst, six
water-miscible organic solvents were tested (ESI, chapter
S5.1†). Of these solvents, DMSO [30% (v/v)] yielded the best ee
and product concentration. Due to the consumption of pyruvic
acid over time, the pH values increased significantly, even in
the buﬀered system (ESI, chapter S5.3.4†). Controlled feeding
of a 3 M pyruvic acid stock solution was used to maintain the
pH values at a constant 6.5 and, at the same time, to provide
pyruvic acid for the reaction. Benzaldehyde was also constantly
fed at a rate that kept its concentration below 50 mM and thus
below the solubility limit of ∼100 mM in the presence of 30%
(v/v) DMSO (ESI, chapter S6†). For the reaction using the
ApPDC-E469G/I468A/W543F variant as crude cell extract, the
formation of up to 320 mM (S)-PAC (corresponding to ∼48
g L−1) was achieved in a 25 mL batch (Fig. 5). After a reaction
time of ten hours, the regioisomer hydroxypropiophenone
(HPP) was the only side product detected, and made up ∼7.5%
of the product mixture. In a similar reaction with wet cells,
only 4% of the product mixture was HPP, and (S)-PAC at a con-
centration of 37.5 g L−1 was obtained (ESI, chapter S6.2†).
As shown in Fig. 5, a decrease of the ee from 95% to 91%
occurred during the course of the reaction. This decrease
seemed to be predominantly caused not by insuﬃcient enzyme
selectivity, but by product instability under the applied reaction
conditions (ESI chapter S6.3†). Furthermore, the presence of
DMSO might have caused the reduced starting ee of 95% (as
earlier reported for ApPDC-E469G9) and enzymatic isomerisa-
tion by other components in the E. coli crude cell extract. Still,
compared to the initial conditions (∼65% with ApPDC-E469G),
91% ee represented a strong increase. By stopping the feed and
adding fresh biocatalyst, a >99% conversion (relative to the
measured benzaldehyde concentration) was obtained, resulting
in the formation of up to 320 mM product. However, if high ee
Fig. 4 Substrate scope of ApPDC wildtype (wt), and the variants ApPDC-E469G, ApPDC-E469G/W543H, and ApPDC-E469G/I468A/W543F with
respect to the enantiomeric excess of the gained product (bar chart) and corresponding percent conversions (table). Reaction conditions: ApPDC-
wt or variant (1.5 mg mL−1, puriﬁed), 50 mM potassium phosphate (pH 6.5), 0.1 mM ThDP, 2.5 mM MgSO4, 10% (v/v) DMSO, 10 mM substituted benz-
aldehyde, 50 mM pyruvate, 20 °C, 600 rpm, 16 h. Percent conversions were determined using GC/MS, and enantiomeric excess by chiral-phase
HPLC; “—” = not determined. (Detailed overview see ESI chapter S7.3†)
Fig. 5 Synthesis of (S)-PAC with ApPDC-E469G/I468A/W543F. Starting
conditions: 100 mM benzaldehyde (BA), 300 mM pyruvate (PYR), 2.5 mM
MgSO4, 0.2 mM ThDP in KPi buﬀer (50 mM, pH 6.5), 30% (v/v) DMSO,
40 mg mL−1 ApPDC-E469G/I468A/W543F (+20 mg mL−1 after 4 h reac-
tion time) as lyophilized crude cell extract; ﬁnal reaction volume of
25 mL. Benzaldehyde was fed (light green) at a rate that kept its concen-
tration below 50 mM (dark green). The pH was kept constant at 6.5 by
online pH measuring and pH-stat using a 3 M pyruvate feed (blue).
PAC = phenylacetylcarbinol. HPP = 2-hydroxypropiophenone. BA =
benzaldehyde. PYR = pyruvate.
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values are required, either a compromise between productivity
and stereoselectivity must be found (e.g., by stopping the
process earlier) or the hydroxyl ketones should be directly
further converted to maintain initially higher selectivities. To
reduce the amounts of byproducts, it is generally advisable to
keep the temperature low (≤25 °C) and reaction times short.
Another solution to prevent the isomerisation of (S)-PAC is
its immediate further conversion, e.g., in a (chemo-) enzymatic
cascade, as we have earlier demonstrated for amino alcohols
like nor(pseudo)ephedrines16
Conclusions
In summary, by a combination of enzyme and reaction engin-
eering, we improved the biocatalytic (S)-PAC synthesis with
respect to industrial requirements such as high stereo-
selectivity (>97%) and high product concentration (up to
320 mM, >48 g L−1) using inexpensive whole cell biocatalysts
or crude cell extracts. Furthermore, a broad range of ring-sub-
stituted (S)-PAC derivatives has been made available for further
synthesis of APIs with high selectivity. The choice of
recommended reaction parameters depends very much on the
requirements of the respective (industrial) application. Our
results demonstrate that competitive biocatalytic processes can
be developed even for very challenging synthetic demands,
such as chemoselective and stereoselective access to (S)-PAC,
by an intelligent combination of enzyme engineering and reac-
tion engineering.
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